

# A Revolutionary Breakthrough In Skin Cancer Detection



VITA IMAGING



## Vita Imaging

We are a medical device company committed to commercializing innovative systems for the detection of cancer. We have the exclusive world-wide rights to revolutionary, patent-protected, platform diagnostic technology from the British Columbia Cancer Agency. Using this technology, we have developed AURA, an award-winning device for the detection of skin cancer. AURA previously achieved market clearance in Canada, the European Union, and Australia. FDA market clearance is pending.

We plan to expand our platform technology to develop products aimed at the detection of internal organ cancers including lung, colon, and oral cancer. Several pilot studies utilizing our game changing platform cancer detection technology have already been published in peer reviewed journals.

## AURA

The AURA is a patent protected, safe, non-invasive imaging and spectroscopy system designed to aid physicians and healthcare professionals in the early detection of skin cancers and pre-cancers by distinguishing between malignant and benign lesions. AURA provides valuable information by identifying spectral changes associated with the biochemistry of skin cancer cells in approximately one second. AURA provides rapid, real-time results, much faster than other skin cancer detection devices in the market.

Vita Imaging Inc.,  
90 Great Oaks Blvd, Suite 206  
San Jose, CA 95119

Contact: Tinh Tran, CEO  
Phone: +1 408-460-9457  
Website: [www.vita-imaging.com](http://www.vita-imaging.com)

\*Aura is not FDA cleared and is not being offered for sale

Doc. No.: MKT-AU-01 Rev C

# Early Detection Saves Lives

AURA helps automate the current process of diagnosis by allowing rapid scanning of suspicious skin lesions and maximizing efficiencies in the workflow by optimizing clinical impact through improved patient outcomes and reduced wait times.

Our cancer detection technology was jointly developed by the Integrative Oncology Dept. - Imaging Unit, BC Cancer Research Centre and the Photomedicine Institute, Department of Dermatology and Skin Science, University of British Columbia. AURA's initial in vivo clinical study was published in Cancer Research.<sup>1</sup>

1. Lui H, Zhao J, McLean D, Zeng H. Real-time Raman spectroscopy for in vivo skin cancer diagnosis. *Cancer Research*. 2012 May 15;72(10):2491-500.

2. Zhao J, Zeng H, Kalia S, Lui H. Incorporating patient demographics into Raman spectroscopy algorithm improves in vivo skin cancer diagnostic specificity. *Translational Biophotonics*. 2019 Dec;1(1-2):e201900016.

A follow-on in vivo independent clinical study published in *Translational Biophotonics* included analyzing the impact of various demographic data on the spectral analysis results. Conducted at the Skin Care Centre at Vancouver Hospital, the study demonstrated AURA sensitivity of 99% with 44.5% specificity, and sensitivity of 95% with specificity of 68.5% (PLS) in identifying skin cancers/pre-cancers (malignant melanoma, basal cell carcinoma, squamous cell carcinoma, and actinic keratosis).<sup>2</sup>

To put these figures into perspective, our leading competitor, DermaSensor, has published study results of 95.5% sensitivity and 20.7% specificity.<sup>3</sup>

3. Merry, S. P., et al. "Clinical performance of novel elastic scattering spectroscopy (ESS) in detection of skin cancer: a blinded, prospective, multi-center clinical trial." *J Clin Aesthet Dermatol* 16.4 Suppl (2023): s16.



“Cancer causes about 1 in every 6 deaths worldwide, more than AIDS, tuberculosis, and malaria combined.”

-The American Cancer Society

## The Facts on Skin Cancer

- Skin cancer is the most common form of cancer in the United States
- 1 out of 3 new cancers diagnosed worldwide will be skin cancer
- 1 out of 5 Americans will develop skin cancer in their lifetime
- Every hour, one person in the United States dies of melanoma
- 50% of people over the age of 65 in the US will be affected by skin cancer
- Between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year
- Survival rate of patients where the disease is detected early is 99%
- 5-Year survival rate of patients with advanced, Stage 4 Melanoma is 30 %
- Annual cost of treating skin cancer in the United States is estimated at \$8 billion USD